Global Autism Spectrum Disorder Therapeutics Market 2018-2022| Funding from Governments of Various Nations to Boost Demand | Technavio
LONDON--(BUSINESS WIRE)--Oct 9, 2018--The global autism spectrum disorder therapeutics market 2018-2022 is expected to post a revenue of around USD 4 billion during the forecast period, according to the latest market research report by .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181009005514/en/
According to analysts at Technavio, the global autism spectrum disorder therapeutics market is expected to post a revenue of around USD 4 billion by 2022. (Graphic: Business Wire)
A key factor driving the growth of the market is funding from governments of various nations. In September 2017, the US NIH announced that it awarded around USD 100 million for the development of interventions for ASD for the next five years. Medicare in Australia has introduced new offers for the diagnosis and early intervention treatment of children with ASD. It covers up to 20 treatment services per child with ASD aged up to 12 years.
This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
In this report, Technavio highlights the rising number of fast track designations as one of the key emerging trends in the global autism spectrum disorder therapeutics market:
Global autism spectrum disorder therapeutics market: Rising number of fast track designations
Pharmaceutical companies receive fast track designations from regulatory bodies to expedite the review and development of investigational therapeutics. This designation offers special support to pharmaceutical companies for the development of their pipeline therapeutics for the treatment of ASD.
“The sponsors who receive fast track designations for their drugs get the benefits such as more frequent written communication from the US FDA regarding the use of biomarkers and design of the proposed clinical trials for the drug being investigated, frequent meetings with the US FDA to discuss the development plan of the drug, and many more,” says a senior analyst at Technavio.
Global autism spectrum disorder therapeutics market: Segmentation analysis
This market research report segments the global autism spectrum disorder therapeutics market by treatment therapeutics (antipsychotic therapeutics and antidepressant therapeutics) and geographical regions (APAC, EMEA, and the Americas).
The Americas led the market in 2017 with a market share of close to 57%, followed by APAC and EMEA respectively. The dominance of the Americas can be attributed to increasing prevalence of ASD and launch of new products which is due to the existence of a strong pipeline.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20181009005514/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 10/09/2018 10:01 AM/DISC: 10/09/2018 10:01 AM